5 news items
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
MRK
1 May 24
for treatment options that have the potential to extend patients' lives," said Dr. Marjorie Green, senior vice president and head of oncology, global
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
MRK
4 Apr 24
mutation in patients with non-small cell lung cancer," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
MRK
28 Mar 24
to advance treatments in earlier stages of lung cancer," said Marjorie Green, senior vice president and head of oncology, global clinical development
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
MRK
4 Mar 24
of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
MRK
23 Feb 24
expression," said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. "We look
- Prev
- 1
- Next